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TranslationsJefferson
Jefferson has a
rich history as 
a university,
teaching hospital,
and premier
research 
institution. In 
the Department
of Medicine, we
strive to honor
this every day,
from patient-centered care to research
breakthroughs that are poised to change
lives around the world. 
This issue of Translations introduces two
recent recruits who are doing just that.
Kathleen Squires, MD, Director of
Infectious Diseases and Environmental
Medicine, is one of the first HIV specialists
to focus on how the virus affects women.
Assistant Professor Donna Woulfe, PhD,
makes great strides in understanding
platelet thrombosis and identifying new
targets for related therapeutics. 
The Department’s efforts continue to
focus on moving discoveries from the
laboratories to the patient’s bedside. 
Our new Center for Vascular Diseases is
but one example of how we translate the
work of researchers like Dr. Woulfe into
clinical care. Tom Force, MD, spearheads
the clinical programs of the growing
Center for Translational Medicine. We
are also proud to welcome a group 
of distinguished new faculty members,
including two division directors, and
honor the faculty’s ever-growing list of
awards, clinical trials, and publications.
As always, we are especially grateful to
our friends and donors who make possible
the continuation of this progressive work
on so many fronts.
Arthur M. Feldman, MD, PhD
Magee Professor of Medicine and 
Chairman of the Department
From the
Chairman
For internationally noted HIV specialist
Kathleen Squires, MD, who joined the
Division of Infectious Diseases and
Environmental Medicine in 2005, the
study of the virus fulfills her childhood
dream of helping people on a personal
level, while also making an impact on the
world at large. 
Dr. Squires brings with her extensive
research in the field of HIV infection,
specifically antiretroviral drug development
and identification of novel treatment
strategies. At the Keck School of
Medicine of the University of Southern
California, she supervised a three-
thousand-patient HIV clinic and was the
Principal Investigator for the USC NIH-
sponsored AIDS Clinical Trials Unit. 
“I was attracted to Jefferson’s Center 
for Human Virology because of the basic
research in HIV at the molecular level,”
says Dr. Squires. “As a clinically based
researcher, I have been eager to do more
translational research in collaboration
with people doing such basic research.” 
At Jefferson, Dr. Squires leads a program
in which the faculty follows HIV patients
who have not had experience with an
integrated, multi-disciplinary HIV program.
Her program manages patients, while
also facilitating clinical research projects
that interact with Jefferson’s basic research
program. “Through collaboration with
Hepatology,” Dr. Squires explains, “we
are able to study patients who are 
not dying of HIV but still affected by
co-infections like Hepatitis B and C and
their complications such as cirrhosis and
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Dr. Kathleen Squires is one of the few HIV 
specialists to study the effects of the virus 
in women. 
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Ongoing Support
Last fall, the Department honored Mrs.
Arline Schwarzman’s generous and 
longtime support of Dr. Arnold Greenspon’s
work in cardiology, which included the
funding of a new electrophysiology lab
that opened in 2005 and was dedicated 
at a ceremony in 2006.
The Department of Medicine is also
immensely grateful for the ongoing generous
support of scleroderma research from the
following families:
For 10 years, the John J. Murray
Foundation and the Datz Family have
been tremendous friends of Jefferson. 
Even after the tragedies of 9/11 personally
affected the family, their commitment 
to scleroderma research inspired 
continued generosity.
Nancy Jones and her late husband
Donald Jones have been supporting our
research for 10 years. 
Standford and Lydia Frank have given to
scleroderma research for 19 years.
For five years, Maurice (Frank) Norman,
PhD, has been a consistent source of 
support for our research. 
With funding from Jefferson friend Arline
Schwarzman, the Cardiac Electrophysiology
Laboratory opened in 2005, including three
rooms for procedures (seen here) and a
waiting area for patients and families.
As a Harvard Medical School student setting
out on his career in 1978, Thomas Force,
MD, sought a path that he thought might
most help patients. He chose cardiology.
Since then, the internationally recognized
physician has made an impact on many
lives through hands-on clinical care and
groundbreaking research. He now brings
this comprehensive experience to Jefferson’s
Center for Translational Medicine, as its
first Clinical Director, in a role that is critical
to the Center’s mission of bridging laboratory
research and bedside care. 
In this position, Dr. Force leads the Center’s
leading-edge basic molecular biomedical
research and its translation into the most
efficient and tailored forms of diagnosis
and treatment as well as modes of 
prevention. “It’s exciting to think that the
work we do in our labs may one day have a
direct effect on the lives of people,” he says. 
Dr. Force’s research interests include the
molecular mechanisms regulating cardiac
hypertrophy – a process of maladaptive
growth of the heart that, if unchecked,
usually leads to heart failure. He also 
studies basic mechanisms that may allow
heart muscle cells to survive ischemic injury
that occurs during myocardial infarction.
Clinical Director Forges New Paths to Health
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He is currently principal investigator for
several National Institutes of Health grants
that support this research.
Dr. Force was previously on faculty at Tufts
University School of Medicine and on the
medical staff at Tufts-New England Medical
Center as well as an investigator at its
Molecular Cardiology Research Institute.
For 15 years he was a researcher with
Massachusetts General Hospital (MGH) 
in Boston and served as Medical Director
of the MGH’s Cardiovascular Health 
Center and Director of the Stress Testing
Laboratories. During that time he was also
an Established Investigator of the
American Heart Association. 
This past summer, Dr. Force and his team
of researchers published a highly influential
study in Nature Medicine about the role 
of the cancer drug Gleevec in causing 
heart failure. The study, which received
international media attention, brings to
light critical issues about pharmaceutical
testing and the need to work across 
disciplines to learn about a drug’s effects.
Quick to praise Gleevec for its ability to
treat difficult and aggressive cancers, Dr.
Force also urges physicians and other 
clinicians to watch their patients taking it
(and drugs like it) for signs of heart problems.
The study has led to a new initiative that
will monitor – through a multinational 
registry – patients treated with Gleevec and
other new cancer agents. Dr. Force and his
team hope to learn which patients are at risk
of heart problems and how to balance the
risk with the drug’s much-needed benefits. 
“There is so much we don’t yet know
about the heart, but we continue to learn
more every day,” says Dr. Force. “I feel
really fortunate to be a part of the Center
and to participate in this kind of progressive
research that translates directly to 
patient care.” ■
Cardiology
Dr. Force (right) and Dr.
Walter Koch direct the clinical
and research activities
(respectively) of the Center
for Translational Medicine.
Force and his team recently
published significant findings
about the cancer drug
Gleevec in Nature Medicine.
Center for Translational Medicine
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Second-year medical 
resident Dae-Hyun Kim,
MD, MPH, has been 
awarded a prestigious 
fellowship in geriatrics to
study cardiovascular aging 
at Harvard University 
following his third year 
training at Jefferson. Dr. Kim,
who was a public health
physician in Korea before coming to Johns
Hopkins to study epidemiology, is primarily
interested in cardiovascular epidemiological
research. His work on heart rate variability
and cognitive impairment in older women
inspired the Harvard invitation. In 2006, Dr.
Kim was awarded an AMA Seed Grant and
will give an oral presentation of his research
on racial disparity in the volume-mortality
3
Having joined the Center in 2005 during
its early stages, Dr. Woulfe recalls that “It
was great to get in on the ground floor and
have a hand in the direction of its growth.”
The collaboration among departments,
divisions, and centers was a huge draw 
for her. “We have a lot of natural 
interaction with the Cardeza Foundation
for Hematological Research. Their expertise
enables us to take our research to a new
level,” she says. 
Dr. Woulfe is gratified by the idea that 
her research can have direct results. “The
beauty of translational medicine is that 
the reward for outcomes extends beyond 
making observations and publishing them –
it means taking the results and developing
them further in new directions,” she
explains. “There are still big holes,
upstream and down, to fill, but when we
find new targets downstream, each one
becomes its own new project.” ■
Donna Woulfe, PhD, a preeminent 
biomedical researcher in the Center for
Translational Medicine, has been interested
in biology since the 9th grade. It wasn’t,
however, until she was exposed to the
biology of blood cell signaling as a graduate
student at the University of Pennsylvania
that she committed a career to biomedicine. 
A principal researcher at the Center and an
Assistant Professor in the Department, Dr.
Woulfe focuses on platelets, one of three
facilitating factors in thrombosis – a serious
and prevalent disease related to all heart
attacks and strokes that involves the 
formation of a clot in a blood vessel. 
Dr. Woulfe’s interest in signaling mechanisms
in platelets concerns how platelets that are
too active may contribute to heart attack
or stroke, while other defects in platelets
may contribute to bleeding. She and her
research assistants, Shelley August, MS,
and Dongjun Lee, PhD, MD, are searching
for new targets for therapeutics related to
thrombosis, by first using mouse models
lacking a particular enzyme and then by
looking for compounds to inhibit the 
same enzyme in people. “Novel signaling
pathways have been shown to be defective
in certain patients, which causes bleeding,
so we now have reasons for a new target.
It’s a fascinating biological problem to strive
to understand,” she says.
Dr. Donna Woulfe
runs Jefferson’s
annual Symposium
in Translational
Cardiovascular
Medicine while 
also conducting 
innovative 
biomedical research.
Woulfe Pioneers Thrombosis Research
Remembering a 
Friend and Colleague 
October 2007 will mark two years
since the Center lost a colleague and
friend, when assistant researcher
Matthew Kuhn died suddenly in his
sleep at age 29. In February 2006, the
staff remembered him at a ceremony
dedicating the plaque, which hangs
outside the conference and library
door. “The plaque, which we pass
every day, is tangible tribute to
Matthew, whose presence is missed
greatly,” says Walter Koch, PhD, 
Director of the Center.
Cardiovascular
relationship in coronary artery bypass surgery
at the American Heart Association’s forum
on Quality of Care and Outcomes Research
in cardiovascular disease in May 2007. 
Dr. Kim was also selected for a Young
Investigator Award at the AHA conference.  
Three posters by residents Saum Shamimi-
Noori, MD, Emanuel Chryssos, MD, and
Mital Sheth, MD, were accepted for the
2007 American College of Cardiology
(ACC) conference in New Orleans. 
Michael Savage, MD, Director of the
Cardiac Catheterization Lab, also led a
team of investigators including Nicholas
Ruggiero, MD, Stuart Gould, MD, and
Heath Saltzman, MD, whose study of
graft re-stenosis was selected for an 
e-poster presentation at this year’s ACC. ■
David Whellan, MD, MHS (second from
right) mentors cardiology fellows and 
residents, including (from left to right)
Nicholas Ruggiero, MD, Emanuel Chryssos,
MD, Saum Shamimi-Noori, MD, and 
Dae-Hyun Kim, MD. Also pictured is 
David L. Fischman, MD (second to left).
Resident Updates
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the least studied. “Because early HIV
research focused exclusively on men, 
we are behind the curve in understanding
the effects of sex and gender as it relates
to toxicity and side effects,” says Squires.
Since joining Jefferson, Dr. Squires has
been developing clinical trials with the HIV
drugs presently available as well as novel
classes of agents. “Current drugs have
converted HIV from being universally fatal
to a chronic disease managed with lifetime
drug therapy,” said Dr. Squires. “People
are now living with HIV, which challenges
us to define how best to use the drugs 
to ensure durable suppression of this viral
infection and a good quality of life for 
the individual.” 
The National Institutes of Health recently
awarded Dr. Squires and her lab a highly
selective grant for the Jefferson HIV
Clinical Trials Unit. Jefferson is one of a
very few new sites in the United States to
receive this seven-year grant, which will
enhance Jefferson’s already established
clinical program and integrate it with a
comprehensive clinical research program. 
Dr. Squires came to Jefferson as part of a
joint recruitment. Her husband, Matthew
Carabasi, MD, a specialist in bone marrow
transplantations whose father and older
brother are also “Jeffersonians,” was
recruited at the same time. He now serves
as the Director of Clinical Investigations at
the Kimmel Cancer Center. ■
A Model for Care and Communication
Approximately 20 to 30 million people of
all ages in the United States are at risk of
developing vascular diseases (diseases
affecting the blood vessels, such as stroke
or aortic aneurysms). Yet with the right
care and education, these diseases are
highly treatable – even preventable. Patients
suffering from or at risk of vascular diseases
can now receive first-rate care and education
all in one centralized location at Jefferson’s
new Center for Vascular Diseases, which
opened in March 2007. 
Developed to help meet the clinical, research,
and educational needs of patients and 
clinicians – including physicians, nurses,
and pharmacists – the state-of-the-art 
and multidisciplinary facility focuses on
diagnosing, treating, and helping patients
manage these disorders. Led by Geno
Merli, MD, and George Tzanis, MD, the
Center collaborates with the Divisions of
Cardiology, Hematology, Cardiovascular/
Interventional Radiology (CVIR), and
Vascular Surgery, as well as the Department
of Neurosurgery. 
For patients, the center is a hub of care
and communication and a visible example of
the Department of Medicine’s commitment
to providing first-rate care that is patient-
friendly. After an initial consultation, the
center’s staff acts as each patient’s personal
advocate, helping to schedule appointments
with specialists and serve as the point of
contact for questions or concerns. They
also follow-up to make sure that patients’
needs and expectations are met. 
For clinicians, the center offers the
opportunity to participate in clinical studies
that help advance our understanding and
treatment of vascular diseases and clinical
disorders. Clinicians also contribute to and
Infectious Diseases: Division
Director Squires Heals Locally 
and Globally
Continued from page 1
liver failure. Multiple studies have 
documented that a major cause of death
for HIV patients in the current era is 
complications from concurrent conditions
such as hepatitis. Such collaborative
research presents a tremendous advantage
to us and our patients.”
Dr. Squires has concentrated much of her
work on the impact of HIV on women,
who globally comprise 50 percent of the
HIV infected population and yet remain
The state-of-the-art Vascular Center meets
the diverse needs of patients, from clinical
care to education.
4
benefit from translational research under
way at the Eugene Feiner Laboratory for
Vascular Atherosclerosis and Thrombosis. 
More information about the Center 
for Vascular Diseases is available online at 
www.jeffersonhospital.org/intmed/
article12040.html. ■
Left to right: George Tzanis, MD, Paul
Bray, MD, and James Fink, MD, attended
the March 2007 reception for the new
Center for Vascular Diseases.
Center for Vascular Diseases
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A Tradition of Caring 
George Zallie, who helped build ShopRite
supermarket from a relative unknown to
one of the largest chains in the region, has
spent his life giving back to the communities
and people who supported and helped him
throughout the years. 
A longtime friend of Jefferson University,
Mr. Zallie’s generosity has made possible
the George Zallie and Family Laboratory
for Cardiovascular Gene Therapy in the
Center for Translational Medicine, which
supports the work of the Center’s Director,
Walter Koch PhD, also the W. W. Smith
Professor of Medicine.
“In a time of ever-shrinking funding,” 
says Dr. Koch, “Mr. Zallie’s commitment 
to Jefferson and support of our lab has
allowed us to stay competitive and 
continue to do cutting-edge molecular 
cardiovascular research.”  
Mr. Zallie, who was born in Ocean City,
New Jersey, grew up helping his parents 
in the “mom-and-pop” store they ran in
Philadelphia’s Fishtown neighborhood (see
bottom right). He traces his philanthropic
nature back to his childhood during the
Depression. One of six children, he saw his
parents, who had emigrated from Albania,
struggle to put food on the table. Yet, they
always helped others who were also hungry. 
“I remember my mother, with no money
and six children to feed, lovingly sharing
what little we had if someone came to 
the door and asked for something to eat,”
says Mr. Zallie. “It was a lesson in giving
and respect that has stayed with me my
entire life.”
This lesson influenced Mr. Zallie’s business
practices as well. Having grown up
steeped in the food and customer service
industry, he opened his own store in 1956,
which set off a long, successful career in
the supermarket business. Now the owner
of eight ShopRite markets in New Jersey,
Mr. Zallie has a reputation for outstanding
customer service as well as for treating his
employees fairly and with honesty and
integrity. He also has three sons and two
grandsons in the business with him.
As he became more successful, Mr. Zallie
began to focus on philanthropy and giving
back to the South Jersey community where
his businesses have prospered. Among 
the many organizations he supports are
Partners in Caring, a community-based
program run by ShopRite, and the Sloan
Kettering Cancer Center.
His gratitude for the care he’s received
from Jefferson physicians over the years –
including doctors Roger Daniels, MD, Barry
George Zallie’s father in front of the
family-owned store at 178 W. Master St.
in the Fishtown section of Philadelphia, c.
1940s. George and his five siblings lived
above the store. 
Giving to Medicine
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private and foundation funds to support
our cutting-edge research, exceptional 
faculty and staff, and patient-centered
care. We are delighted to welcome
Margaret Fala, MBA, CFRE, as our new
Director of Development. Ms. Fala comes
with extensive experience in health care
development, including as Director of
Development for Holy Redeemer Health
System and as Director of Marketing and
Development for SERV Behavioral Health
In an age of dwindling
public monies, the
Department of
Medicine faces ever-
growing needs for 
Department Recruits New Director of Development
Margaret Fala, MBA,
CFRE, joined Jefferson
in March 2007.
System, Inc. Ms. Fala has also worked with
The Perrier Group of America and Bryn
Mawr College.
If you are interested in making a gift to
any one of the Department’s divisions 
or would like to learn about targeted 
or general funding opportunities within
the Department, please contact Ms. Fala 
at margaret.fala@jefferson.edu or
215-955-7556. ■
Goldberg, MD, and Howard Weitz, MD –
led to his generous gift of the new laboratory. 
“I am particularly pleased to support the
groundbreaking heart failure research
being done at the Center for Translational
Medicine,” Mr. Zallie says. “I have referred
many people to the program at Jefferson,
and I am confident that the research 
they are doing will make a tremendous 
difference in generations to come.”
The work of the lab that Mr. Zallie made
possible continues to flourish: Recent 
clinical research has expanded, and the lab
received funding to study more than 400
patients in different stages of heart failure
and correlate their cardiac contractile
function with an enzyme found in white
blood cells. Additionally, the lab published
a groundbreaking study in Nature Medicine
(see page 2) and expects to publish 
another study in Circulation in 2007. ■
The generosity of George Zallie (center,
with Walter Koch, PhD, left, and his 
physician Howard Weitz, MD, right) has
made possible the Center for Translational
Medicine’s George Zallie and Family
Laboratory for Cardiovascular Gene Therapy
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Awards and Honors
Anastasios Lymperopoulos, PhD, Post-
Doctoral Fellow, Center for Translational
Medicine, was a finalist for the Melman
Marcus Award.
Leif Erik Vinge, MD, PhD, Center 
for Translational Medicine, received a 
2006-2007 Fullbright Scholar grant. 
Charlene Williams, PhD, Professor of
Medicine and Associate Director of Research,
Division of Rheumatology, received the
Arthritis Foundation of Eastern Pennsylvania’s
2006 Stewart J. McCracken Award for the
highest-rated research project in the
Philadelphia area. Dr. Williams and her 
colleagues discovered that one type 
of inherited arthritis, called familial 
chondrocalcinosis, is caused by mutations 
in a novel gene, termed
ANKH. Funding from
the Arthritis Foundation
is helping Dr. Williams
and her team to under-
stand the structure and
function of ANKH.
New Division Directors Paul Bray, MD
(left), and Joseph Cheung, MD, PhD.
Department of Medicine
1025 Walnut Street, Suite 822
Philadelphia, PA 19107-5083
Non-Profit Org.
U.S. Postage
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The Division of Nephrology has added several
new faculty: Jianliang Song, PhD, Xueqian
Zhang, MD, and Sonia Camphor, MD.
Ying Jin, MD, PhD, joins the Division of
Hematology.
New to the Division of Gastoenterology
and Hepatology is Patricia Kozuch, MD.
Michael Baram, MD, joins the Division 
of Critical Care, Pulmonary, Allergic, and
Immunologic Diseases.
Joining the Division of Rheumatology as
Clinical Director is Oscar Irigoyen, MD,
who was previously on the faculty at
Columbia Presbyterian.
Welcome New Faculty
The Department of Medicine welcomes
new division directors Paul Bray, MD, in
Hematology and Joseph Cheung, MD,
PhD, in Nephrology.
We also welcome all new faculty, including
the following individuals (as of May 2007): 
Babu Jasti, MD, has joined the Division 
of Cardiology. 
Kevin Furlong, DO, Mahadev
Kalyankar, PhD, Ming-Lin Liu, MD, PhD,
and Ziangdong Wu, MD, PhD, joined the
Division of Endocrinology. 
The Division of Internal Medicine adds five
members: Anthony Macchiavelli, MD,
Reetika Padha, MD, Jessica Salt, MD,
George Tzanis, MD, and Bo Kim, MD. 
The Division of Infectious Diseases welcomes
Elias Argyris, PhD, and Rajnish Dave, PhD.
Karsten Peppel, PhD, and Patrick Most,
MD, have joined the Center for
Translational Medicine.
Faculty News
Dr. Charlene Williams
leads the field in
research on arthritis. 
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